VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report published on Saturday. The brokerage issued a sell rating on the stock.

A number of other equities research analysts also recently commented on the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, December 10th.

VolitionRx Stock Performance

VNRX opened at $0.63 on Friday. The company has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.66. The firm has a market capitalization of $58.66 million, a PE ratio of -1.76 and a beta of 1.17. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.